Article
ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients.
Oncotarget - 23 Aug 2016
Li Ziyu, Xing Xiaofang, Shan Fei, Li Shuangxi, Li Zhongwu, Xiao Aitang, Xing Zhaodong, Xue Kan, Li Zhemin, Hu Ying, Jia Yongning, Miao Rulin, Zhang Lianhai, Bu Zhaode, Wu Aiwen, Ji Jiafu
Abstract excerpt
Several studies have evaluated the efficacy of neoadjuvant treatment using oxaliplatin and fluoropyrimidines in advanced gastric cancer (GC). However, preoperative biomarkers predictive of clinical outcome remain lacking. We examined polymorphisms in the MTHFR, DPYD, UMPS, ABCB1, ABCC2, GSTP1, ERCC1, and XRCC1 genes to evaluate their usefulness as pharmacogenetic markers in a cohort of 103 GC patients treated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.